These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Carcinogenic risks of dioxin: mechanistic considerations. Schwarz M; Appel KE Regul Toxicol Pharmacol; 2005 Oct; 43(1):19-34. PubMed ID: 16054739 [TBL] [Abstract][Full Text] [Related]
23. Non-genotoxic carcinogens: early effects on gap junctions, cell proliferation and apoptosis in the rat. Mally A; Chipman JK Toxicology; 2002 Dec; 180(3):233-48. PubMed ID: 12393293 [TBL] [Abstract][Full Text] [Related]
24. Mechanisms of non-genotoxic carcinogens and importance of a weight of evidence approach. Hernández LG; van Steeg H; Luijten M; van Benthem J Mutat Res; 2009; 682(2-3):94-109. PubMed ID: 19631282 [TBL] [Abstract][Full Text] [Related]
25. Mode-of-action analysis for induction of rat liver tumors by pyrethrins: relevance to human cancer risk. Osimitz TG; Lake BG Crit Rev Toxicol; 2009; 39(6):501-11. PubMed ID: 19463055 [TBL] [Abstract][Full Text] [Related]
26. Toxicogenomics and cancer risk assessment: a framework for key event analysis and dose-response assessment for nongenotoxic carcinogens. Bercu JP; Jolly RA; Flagella KM; Baker TK; Romero P; Stevens JL Regul Toxicol Pharmacol; 2010 Dec; 58(3):369-81. PubMed ID: 20801182 [TBL] [Abstract][Full Text] [Related]
27. Inhibitory effect of α-lipoic acid on thioacetamide-induced tumor promotion through suppression of inflammatory cell responses in a two-stage hepatocarcinogenesis model in rats. Fujii Y; Segawa R; Kimura M; Wang L; Ishii Y; Yamamoto R; Morita R; Mitsumori K; Shibutani M Chem Biol Interact; 2013 Sep; 205(2):108-18. PubMed ID: 23830814 [TBL] [Abstract][Full Text] [Related]
28. Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Grasl-Kraupp B; Ruttkay-Nedecky B; Müllauer L; Taper H; Huber W; Bursch W; Schulte-Hermann R Hepatology; 1997 Apr; 25(4):906-12. PubMed ID: 9096596 [TBL] [Abstract][Full Text] [Related]
29. The tumor-promoting activity of 2-acetylaminofluorene is associated with disruption of the p53 signaling pathway and the balance between apoptosis and cell proliferation. Pogribny IP; Muskhelishvili L; Tryndyak VP; Beland FA Toxicol Appl Pharmacol; 2009 Mar; 235(3):305-11. PubMed ID: 19167416 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two-year bioassay is no longer necessary. Cohen SM Toxicol Pathol; 2010 Apr; 38(3):487-501. PubMed ID: 20215581 [TBL] [Abstract][Full Text] [Related]
31. Differential gene expression profiling between genotoxic and non-genotoxic hepatocarcinogens in young rat liver determined by quantitative real-time PCR and principal component analysis. Suenaga K; Takasawa H; Watanabe T; Wako Y; Suzuki T; Hamada S; Furihata C Mutat Res; 2013 Feb; 751(1):73-83. PubMed ID: 23183053 [TBL] [Abstract][Full Text] [Related]
32. Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Ellinger-Ziegelbauer H; Stuart B; Wahle B; Bomann W; Ahr HJ Mutat Res; 2005 Aug; 575(1-2):61-84. PubMed ID: 15890375 [TBL] [Abstract][Full Text] [Related]
33. Dose-response approaches for nuclear receptor-mediated modes of action for liver carcinogenicity: Results of a workshop. Andersen ME; Preston RJ; Maier A; Willis AM; Patterson J Crit Rev Toxicol; 2014 Jan; 44(1):50-63. PubMed ID: 24083384 [TBL] [Abstract][Full Text] [Related]
34. Differences in DNA damage and repair produced by systemic, hepatocarcinogenic and sarcomagenic dibenzocarbazole derivatives in a model of rat liver progenitor cells. Valovicová Z; Marvanová S; Mészárosová M; Srancíková A; Trilecová L; Milcová A; Líbalová H; Vondrácek J; Machala M; Topinka J; Gábelová A Mutat Res; 2009 Jun; 665(1-2):51-60. PubMed ID: 19427511 [TBL] [Abstract][Full Text] [Related]
35. The use of structure-activity relationships and markers of cell toxicity to detect non-genotoxic carcinogens. Combes RD Toxicol In Vitro; 2000 Aug; 14(4):387-99. PubMed ID: 10906445 [TBL] [Abstract][Full Text] [Related]
36. Concordance of transcriptional and apical benchmark dose levels for conazole-induced liver effects in mice. Bhat VS; Hester SD; Nesnow S; Eastmond DA Toxicol Sci; 2013 Nov; 136(1):205-15. PubMed ID: 23970803 [TBL] [Abstract][Full Text] [Related]
37. Involvement of multiple cell cycle aberrations in early preneoplastic liver cell lesions by tumor promotion with thioacetamide in a two-stage rat hepatocarcinogenesis model. Kimura M; Fujii Y; Yamamoto R; Yafune A; Hayashi SM; Suzuki K; Shibutani M Exp Toxicol Pathol; 2013 Nov; 65(7-8):979-88. PubMed ID: 23474136 [TBL] [Abstract][Full Text] [Related]
38. Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals. Lake BG Annu Rev Pharmacol Toxicol; 1995; 35():483-507. PubMed ID: 7598504 [TBL] [Abstract][Full Text] [Related]
39. Transcriptomic responses generated by hepatocarcinogens in a battery of liver-based in vitro models. Doktorova TY; Yildirimman R; Vinken M; Vilardell M; Vanhaecke T; Gmuender H; Bort R; Brolen G; Holmgren G; Li R; Chesne C; van Delft J; Kleinjans J; Castell J; Bjorquist P; Herwig R; Rogiers V Carcinogenesis; 2013 Jun; 34(6):1393-402. PubMed ID: 23393228 [TBL] [Abstract][Full Text] [Related]
40. Different inhibitory effects in the early and late phase of treatment with KAT-681, a liver-selective thyromimetic, on rat hepatocarcinogenesis induced by 2-acetylaminofluorene and partial hepatectomy after diethylnitrosamine initiation. Hayashi M; Tamura T; Kuroda J; Ohnota H; Shibata N; Akahane M; Kashida Y; Mitsumori K Toxicol Sci; 2005 Mar; 84(1):22-8. PubMed ID: 15564315 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]